EUVIMEDEUVIMED entdecken
Multizentrische Studie

A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study

V W Nielsen iD, C B Johansen iD, T Todberg iD, L Skov iD, C V Nissen iD, R Dodge, A Egeberg iD, J P Thyssen iD, S F Thomsen iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19690 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von V W Nielsen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Novartis Healthcare A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about the therapeutic benefits of a value‐based healthcare model compared to a traditional activity‐based incentive model in psoriasis (PsO).

Objectives

This prospective non‐interventional study evaluated an outcome‐based, patient‐centred management model for patients with PsO.

Methods

In total, 49 patients with a Psoriasis Area and Severity Index (PASI) ≥3 who were starting or switching between treatments were included. Patients were assessed at baseline, 3 and 9 months. The patient benefit index (PBI) was calculated using predefined questionnaires. An expected PBI was calculated and adjusted for risk factors known to complicate treatment, that is overweight and smoking. The model remunerated the department on whether the observed PBI exceeded the expected PBI to incentivize over‐performance.

Results

In total, 40 patients (80%) completed all three visits; 32.7% were smokers and 73.5% were overweight. Mean PASI at baseline was 11.5 (SD 9.1); PASI improved significantly from baseline through 3 months: mean reduction, 8.0 (SD 9.2), p < 0.001 and was maintained until 9 months: mean further reduction, 0.1 (SD 3.3), p = 0.893. The mean PBI was 2.5 (SD 1.3) and 2.8 (SD 1.1) at 3 and 9 months, respectively. A PBI ≥1 was achieved by 87.8% at 3 and 95.1% at 9 months. Overall, the department was remunerated a mean 2721.1 DKK (SD 4472.8) per patient. In subgroup analysis, the department was remunerated a mean of, respectively, 2428.6 (SD 5089.5), 2636.6 (SD 4471.3) and 3196.5 (SD 4497.1) DKK for patients with none, 1 or 2 risk factors, that is smoking or/and overweight.

Conclusions

The model evaluated herein is the first value‐based model to calculate remuneration from patient reported outcomes and showed to successfully predict the expected PBI and remunerate treatment based on whether the expected treatment goal was met or exceeded. This can be utilized in the patient‐centred management of PsO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansProspective StudiesMaleFemaleMiddle AgedAdultSeverity of Illness IndexAgedPatient-Centered CareDermatologic AgentsValue-Based Health Care

Substanzen

Dermatologic Agents

Autor:innen und Institutionen

  • Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Novartis Healthcare A/S, Copenhagen, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: V W Nielsen, C B Johansen, T Todberg, L Skov, C V Nissen, A Egeberg, J P Thyssen, S F Thomsen

Förderung

  • Novartis Healthcare A/S

Zitieren

APA

Nielsen, V. W., Johansen, C. B., Todberg, T., Skov, L., Nissen, C. V., Dodge, R., Egeberg, A., Thyssen, J. P., & Thomsen, S. F. (2024). A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19690

Vancouver

Nielsen VW, Johansen CB, Todberg T, Skov L, Nissen CV, Dodge R, et al. A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19690

BibTeX
@article{Nielsen2024,
  author = {Nielsen, V W and Johansen, C B and Todberg, T and Skov, L and Nissen, C V and Dodge, R and Egeberg, A and Thyssen, J P and Thomsen, S F},
  title = {A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19690}
}
Kostenlos starten →